AGP Executive Report
Last update: 9 hours agoBrain Research: University of Zurich scientists found that support cells in adult mouse brains can multiply and refill damaged areas, pointing to a potential new avenue for treating brain disorders. Similar cells were observed in tissue from people with a rare neurological disease. Bioelectronics: ETH Zurich researchers have developed a wireless implant that lowered blood sugar in diabetic mice by converting excess glucose into a compound the body can remove. It remains experimental and is years from human trials. Swiss Pharma: Novartis’s pelacarsen sharply reduced a cardiovascular risk marker in a major trial but did not significantly cut heart attacks, strokes or related deaths, raising questions about the drug’s clinical value. Robotics: ABB and SoftBank are reportedly exploring a separate ownership structure for ABB’s China robotics business after Beijing blocked their $5.4 billion deal. China accounts for about 30% of ABB Robotics’ business. Swiss Tech: Dental startup vVardis is targeting a valuation of up to $4.4 billion in a planned US IPO.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
